Doravirine dose testing during pregnancy for breastfeeding mothers
Treatments studied
Part of Infections clinical trials.
This study tests how to best dose doravirine for pregnant people with HIV who plan to breastfeed after delivery. The goal is to keep the HIV treatment working safely for both pregnancy and breastfeeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give consent for the study
- You are pregnant with HIV and started combination HIV treatment between 12 and under 26 weeks pregnant
- You plan to breastfeed your baby after birth
- You have not taken any HIV combination treatment in the last 6 months
- You do not have severe liver inflammation from hepatitis B or very high liver blood tests
- You are not taking certain medicines that can lower doravirine levels (like rifampicin or St. John’s wort)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This study tests switching your current HIV medicines to a once-daily pill combining doravirine, tenofovir, and lamivudine, specifically for people whose virus has a past M184V mutation but is now well controlled.
This trial studies how the HIV drug dolutegravir works in people who also have depression. Participants will receive an antidepressant called fluoxetine to see how it affects the HIV treatment.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.